Kaan Harmankaya
25 works · 5,303 citations · h-index 15
Top works
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
- Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- Dermatoscopic Findings of Cutaneous Mastocytosis
- Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials
- Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.
- Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
- Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody.
- On Analyzing Process Compliance in Skin Cancer Treatment: An Experience Report from the Evidence-Based Medical Compliance Cluster (EBMC2)
- Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma
- A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody
- 9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials
- 9317 Ipilimumab re-induction after progression in patients with advanced melanoma enrolled in Phase II clinical trials
- Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials.
- Dermatitis linearis outbreak associated with Paederus balcanicus in Austria
- 9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors